

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))				APPLICANT Keith Moore			
				FILING DATE October 8, 2003	GROUP 1714		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>ll</i>	A.L	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
<i>ll</i>	A.R	Dahl, Svein G., <u>Pharmacokinetics of methotriptazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442					
<i>ll</i>	A.S	Dahl, Svein, G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40					
<i>VJ</i>	A.T	Dahl, Svein G, et al., <u>Plasma and Erythrocyte Levels of Methotriptazine and Two of Its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87					
EXAMINER	<i>Chat Chabal</i>			DATE CONSIDERED 8/24/2006			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							